1 Ocak 2020 Dergi makalesi Açık Erişim

Balcioglu, Bertan Koray; Oncu, Melis Denizci; Ozturk, Hasan Umit; Yucel, Fatima; Kaya, Filiz; Serhatli, Muge; Polat, Hivda Ulbegi; Tekin, Saban; Bahadir, Aylin Ozdemir

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/89241</identifier>
  <creators>
    <creator>
      <creatorName>Balcioglu, Bertan Koray</creatorName>
      <givenName>Bertan Koray</givenName>
      <familyName>Balcioglu</familyName>
      <affiliation>TUBITAK, Genet Engn &amp; Biotechnol Inst, Marmara Res Ctr, Kocaeli, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Oncu, Melis Denizci</creatorName>
      <givenName>Melis Denizci</givenName>
      <familyName>Oncu</familyName>
      <affiliation>TUBITAK, Genet Engn &amp; Biotechnol Inst, Marmara Res Ctr, Kocaeli, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Ozturk, Hasan Umit</creatorName>
      <givenName>Hasan Umit</givenName>
      <familyName>Ozturk</familyName>
      <affiliation>TUBITAK, Genet Engn &amp; Biotechnol Inst, Marmara Res Ctr, Kocaeli, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Yucel, Fatima</creatorName>
      <givenName>Fatima</givenName>
      <familyName>Yucel</familyName>
      <affiliation>TUBITAK, Genet Engn &amp; Biotechnol Inst, Marmara Res Ctr, Kocaeli, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Kaya, Filiz</creatorName>
      <givenName>Filiz</givenName>
      <familyName>Kaya</familyName>
      <affiliation>TUBITAK, Genet Engn &amp; Biotechnol Inst, Marmara Res Ctr, Kocaeli, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Serhatli, Muge</creatorName>
      <givenName>Muge</givenName>
      <familyName>Serhatli</familyName>
      <affiliation>TUBITAK, Genet Engn &amp; Biotechnol Inst, Marmara Res Ctr, Kocaeli, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Polat, Hivda Ulbegi</creatorName>
      <givenName>Hivda Ulbegi</givenName>
      <familyName>Polat</familyName>
      <affiliation>TUBITAK, Genet Engn &amp; Biotechnol Inst, Marmara Res Ctr, Kocaeli, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Tekin, Saban</creatorName>
      <givenName>Saban</givenName>
      <familyName>Tekin</familyName>
    </creator>
    <creator>
      <creatorName>Bahadir, Aylin Ozdemir</creatorName>
      <givenName>Aylin Ozdemir</givenName>
      <familyName>Bahadir</familyName>
      <affiliation>TUBITAK, Genet Engn &amp; Biotechnol Inst, Marmara Res Ctr, Kocaeli, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Sars-Cov-2 Neutralizing Antibody Development Strategies</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2020</publicationYear>
  <dates>
    <date dateType="Issued">2020-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/89241</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.3906/biy-2005-91</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targeted-therapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARS-CoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.</description>
  </descriptions>
</resource>